pages/clinical.md
... ...
@@ -10,11 +10,12 @@ link-citations: true
10 10
11 11
|Gene|Status|Entity|Therapy|Biomarkers|
12 12
|-|:--|-|:---|:-----|
13
-|[BCL2](/BCL2)|ongoing|DLBCL|venetoclax|Not applicable|
14
-|[BTK](/BTK#clinical-relevance)|ongoing|DLBCL|ibrutinib|ABC gene expression signature, MCD genetic subgroup|
15 13
|[CD79B](/CD79B#clinical-relevance)|FDA approved|DLBCL|polatuzumab vedotin|ABC gene expression signature|
16 14
|[EZH2](/EZH2#clinical-relevance)|FDA approved|FL|tazemetostat|Mutation|
17 15
|[XPO1](/XPO1#clinical-relevance)|FDA approved|DLBCL|selinexor|Not applicable|
16
+|[BCL2](/BCL2)|ongoing|DLBCL|venetoclax|Not applicable|
17
+|[BTK](/BTK#clinical-relevance)|ongoing|DLBCL|ibrutinib|ABC gene expression signature, MCD genetic subgroup|
18
+
18 19
19 20
20 21
## References